(Alliance News) - Open Orphan PLC on Wednesday said it has signed a contract with US-based biopharmaceutical firm SFA Therapeutics.
Open Orphan said it is "delighted" to support SFA Therapeutics in the development of its novel treatment. The drug consulting services platform said its subsidiary Venn Life Sciences will provide SFA Therapeutics with assistance in the filing of a European Medicines Agency application.
Open Orphan said this is an important contract as it is the first time that Venn has utilised Open Orphan's expertise in filing a European Medicines Agency application for a North American company, which already has a US Food & Drug Administration Orphan drug designation.
"This contract is a further demonstration of delivery against one of Open Orphan's key objectives, transforming Venn," said Open Orphan Chief Executive Cathal Friel.
"The contract is an exciting one as we are now building on our capability by actively winning work in the fast-growing orphan drug sector," added Friel.
Open Orphan shares were trading 2.7% higher in London on Wednesday morning at 5.80 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.